Evidence‑Based Criteria for Redo Mitral Valve Surgery

Preoperative Echocardiographic and Hemodynamic Thresholds

Transthoracic echocardiography should identify left‑ventricular ejection fraction < 60 % as a marker of ventricular dysfunction that influences operative planning. [@1]
A left‑ventricular end‑systolic dimension ≥ 40 mm on TTE signals the need for surgical intervention on the mitral valve. [@3]
Pulmonary‑artery systolic pressure > 50 mmHg on TTE is considered concerning and warrants closer peri‑operative evaluation. [@3]
Severe tricuspid insufficiency more than doubles the risk of mortality after redo mitral surgery and should be addressed when feasible. [@2]

Low‑risk candidates are asymptomatic, have stable prosthetic valve function, LVEF > 50 %, no pulmonary hypertension, and controlled atrial fibrillation. [@2]
Moderate‑risk patients present with mild symptoms (NYHA I‑II), LVEF 30‑50 %, or mild‑moderate pulmonary hypertension and require enhanced monitoring and cardiology input. [@2]
High‑risk patients exhibit NYHA III‑IV symptoms, LVEF < 30 %, severe pulmonary hypertension, prosthetic valve dysfunction, or active endocarditis, and should undergo mandatory cardiology consultation before proceeding. [@2]

Candidates must have severe, chronic primary mitral regurgitation with NYHA III‑IV symptoms and a life expectancy that justifies intervention. [@3]
Acceptable anatomic criteria include left‑ventricular ejection fraction between 20 % and 50 %, left‑ventricular end‑systolic dimension ≤ 70 mm, and pulmonary‑artery systolic pressure ≤ 70 mmHg. [@1]
Adequate valve morphology on transesophageal echocardiography is required to ensure successful device deployment. [@1]

Operative mortality for mitral valve repair is roughly half that observed with replacement, supporting repair as the preferred strategy when feasible. [@3]
Repair preserves left‑ventricular function better than replacement, reducing postoperative ventricular dysfunction. [@3]
Repair avoids prosthetic‑related complications such as thromboembolism, anticoagulation‑related bleeding, and structural valve deterioration. [@3]
Replacement should be chosen when the valve morphology is unfavorable, when a high risk of recurrent regurgitation is anticipated, or when extensive tissue destruction from active endocarditis is present. [@5]
For ischemic mitral regurgitation, repair using a small undersized rigid annuloplasty ring is recommended, and chordal‑sparing techniques should be employed during replacement to preserve ventricular function. [@1]

Mechanical prosthetic valve thrombosis that occurs despite optimal anticoagulation warrants reoperation with a bioprosthetic valve. [@6]
In ideal candidates treated at high‑volume centers, operative mortality for isolated mitral valve repair is expected to be < 1 %. [@4]
Freedom from reoperation after mitral repair exceeds 95 % at 15‑20 years, and freedom from recurrent moderate‑to‑severe regurgitation exceeds 80 % over the same interval. [@4]

A right minithoracotomy (3–4 cm incision in the fourth intercostal space) combined with femoral cardiopulmonary bypass and transthoracic aortic occlusion is recommended to avoid sternal re‑entry and reduce injury to patent grafts. [@4]
Meticulous pre‑operative CT angiography is essential to evaluate vascular anatomy, chest‑wall thickness, and aortic calcification before minimally invasive access. [@4]
Careful intra‑operative de‑airing and inspection of all port sites before closure are critical to prevent cerebrovascular events and postoperative hemorrhage. [@4]